Current preclinical and clinical studies are actively investigating therapeutic strategies targeting FOXP3+Tregs, specifically UP-Treg and DOWN-Treg, for the treatment of autoimmune diseases, tumors, infectious diseases (including COVID-19), improvement of islet β cell function in diabetes patients, and promotion of tissue repair. The gene discussed is FOXP3; the disease is COVID-19.